[6]
Leo, A.; De Caro, C.; Nesci, V.; Tallarico, M.; De Sarro, G.; Russo, E. Modeling poststroke epilepsy and preclinical development of drugs for poststroke epilepsy. Epilepsy Behav., 2020, 104(Pt B), 106472.
[7]
Ferlazzo, E.; Gasparini, S.; Beghi, E.; Sueri, C.; Russo, E.; Leo, A. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. Epilepsia, 2016, 57(8), 1205-1214.
[9]
Leo, A.; Citraro, R.; Tallarico, M.; Iannone, M.; Fedosova, E.; Nesci, V. Cognitive impairment in the WAG/Rij rat absence model is secondary to absence seizures and depressive-like behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 94, 109652.
[11]
Tallarico, M.; Pisano, M.; Leo, A.; Russo, E.; Citraro, R.; De Sarro, G. Antidepressants drugs for seizures and epilepsy: Where do we stand? Curr. Neuropharmacol., 2022, 21, 1691-1713.
[14]
Miziak, B.; Czuczwar, S.J.; Pluta, R. Comorbid epilepsy and depression-pharmacokinetic and pharmacodynamic drug interactions. Front. Pharmacol., 2022, 13, 988716.
[16]
Fortunato, F.; Giugno, A.; Sammarra, I.; Labate, A.; Gambardella, A. Epilepsy, immunity and neuropsychiatric disorders. Curr. Neuropharmacol., 2022, 21, 1714-1735.
[17]
Tan, T.H.L.; Perucca, P.; O’Brien, T.J.; Kwan, P.; Monif, M. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease. Epilepsia, 2021, 62(2), 303-324.
[18]
Rollo, E.; Romozzi, M.; Vollono, C.; Calabresi, P.; Geppetti, P.; Iannone, L.F. Antiseizure medications for the prophylaxis of migraine during the anti-CGRP drugs era. Curr. Neuropharmacol., 2022, 21, 1767-1785.
